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in relation to stroke or systemic embolism and mean rank 1.15 for major bleeding. 
Edoxaban (60mg od) was also highly ranked (means 3.24 and 1.92, respectively). We 
did not see strong evidence that NOACs have advantages over LMWH in primary 
prevention, or over warfarin in acute treatment and secondary prevention of VTE, but 
risk of bleeding complications was lower for some NOACs than for warfarin. In sen-
sitivity analyses, key decisions we made in the process did not materially affect the 
results. ConClusions: NOACs have advantages over warfarin for stroke prevention 
in AF and acute treatment of VTE, but we found no evidence that they should replace 
the standard treatments for primary and secondary prevention of VTE.
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Assessment of A PrediCtiVe risk model for ClAssifying PAtients with 
multimorbidity in the bAsque Country
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objeCtives: To describe the rate of unplanned admissions in patients with multi-
morbidity and calculate the percent of patients with at least one unplanned admis-
sion by risk classification based on the results of a predictive model Methods: 
Cross-sectional study. In September 2013 all Basque Country citizens were classified 
in risk groups based on a prediction model that used data from a 2 year period: 
age, sex, diagnoses, procedures, prescriptions and costs from the first year as the 
explanatory variables and healthcare cost in the second year as the dependent 
one. A Patient with multimorbidity was defined as following: 2 or 3 from diabetes, 
chronic obstruction pulmonary disease and chronic heart failure; or multimorbid-
ity definition used by Ollero et al published elsewhere. People younger than 14 or 
with a diagnosis of cancer, a transplant or dialysis were excluded. Multimorbidity 
was classified in three risk groups based on the expected healthcare cost percen-
tiles (< 75; 75-95; > 95). Case-mix Adjusted Clinical Groups (ACG) was used for both 
prediction and definition of multimorbidity. Rate of unplanned admissions and the 
probability of one or more unplanned admissions by risk group during the follow-
ing year to their classification were calculated Results: A total of 24,247 people 
met the criteria of multimorbidity (61.3%males) with a mean age of 75.5 years. 
2,795 were classified as low-risk, 10,598 as medium-risk and 10,853 as high-risk. 
The rate of unplanned admissions was 148.4/1000 in the low-risk group, 340.3/1000 
in the medium-risk group and 861.6/1000 in the high-risk group (Mantel-Haenszel 
trend test p< 0,001). 11.4%, 22.8% and 44.6% of the patients in each risk group 
required one or more unplanned admissions during the following year, respectively 
(p< 0,001) ConClusions: Predictive risk models, based on ACG, allow classifying 
patients with multimorbidity in risk groups. This makes possible a better develop-
ment of personalized, cost-efficient and patient-centered care plans
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objeCtives: Update epidemiology and estimate Chronic Heart Failure (CHF) related 
costs in general practice setting Methods: We used Health Search, an Italian gen-
eral practice database formed by about 1,000 GPs. We collected demographics, clini-
cal informations, drug prescriptions, co-morbidities, and lifestyle measurements, 
reflecting “real world” practice. Results: We analyzed data of 13,633 CHF (mean 
age was 76.78 years) patients that resulted in a prevalence of 1.25%. We observed 
similar prevalence in men and women; prevalence increased significantly with age, 
in both men and women. There were some substantial differences across regions 
(eg.: Emilia Romagna 1.54% vs. Sardinia 0.61%). Incidence rate was slightely lower 
than that reported in the literature (1.99*1000 person-years) with some regional 
diffrences: 3.24*1000 Emilia Romagna as oposed to 1.21*1000 in Puglia and Marche. 
Women had a higher incidence rate than men (2.05*1.000 vs. 1.92*1000). Overall, 
mean cost in a cohort of 7.710 patients (excluding 67,7% of patients that had a null 
cost registrated by phisicians) was 950.22€ /patient/year (DS: 1135,27), while median 
cost was 643,16€ . Age and NYHA class seemed to influence costs for elderly patients, 
while ex-smokers, alcohol abusers and patients with alcohol related diseases had a 
significant reduction of costs. ConClusions: Real world data is needed to under-
stand the epidemiology of and costs due to CHF in primary care. The epidemiology 
of CHF here reported is in line with current literature. Concerning CHF-related costs 
and the respective determinants, this is the first study examining the Italian general 
practice setting. The present analysis gives an important contribution in updating 
epidemiology and estimating CHF-related costs.
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objeCtives: Hypertriglyceridemia (HTG) is a common condition characterized 
by elevated triglyceride (TG) levels with the threshold inconsistently defined but 
often appearing as ≥ 2.26 mmol/L; patients with TG levels ≥ 5.6 mmol/L have severe 
HTG (sHTG). The objective of this study was to evaluate the burden of HTG and 
report unmet needs. Methods: MEDLINE- and Embase-indexed databases were 
systematically searched, pairing keywords for elevated TG levels with outcomes, to 
identify English-language articles published from 1/1/2002–4/14/2014. Conference 
proceedings from the past four years were also reviewed. Studies evaluating clini-
cal, patient-centered, economic, and epidemiologic outcomes in adults with TG 
levels ≥ 2.26 mmol/L were included. Results: Of the 1,225 articles identified, 160 
studies were included. Prevalence of HTG (1.2%–55.8% globally) was reported incon-
sistently. Significant associations were identified between HTG and cardiovascular 
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AdVerse drug reACtions, mediCAtion AdherenCe And PhysiCiAns’ 
PresCribing behAVior: whiCh relAtionshiP? A dAtAbAse AnAlysis on 
stAtin use
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objeCtives: Pharmacological adherence plays an essential role in controlling hyper-
cholesterolemia. Pharmacological care is also affected by the prescribing inappro-
priateness and adverse drug reactions (ADRs). ADRs can lead to a perceived lack of 
therapy effectiveness and subsequent suboptimal adherence. Our aim was to evaluate 
the impact of statin-induced, muscle-related ADRs on patients’ therapy adherence, 
and how this relationship may compromise the efficacy of physicians’ prescribing 
choices and health outcomes in clinical practice Methods: A retrospective cohort 
study was performed using data from databases of 4 Local Health Units (LHUs) located 
in Emilia-Romagna, Toscana and Umbria regions, with an overall population of about 
1.1 millions of inhabitants. All subjects aged≥ 18 years with a first prescription for 
statins in the period 01/01/2007-30/06/2008 were included. Baseline and follow-up 
LDL-C levels were considered Results: A total of 71,855 patients (51% men, age 
68.6±10.6) were included. Among them, 31,544 (43.9%) had ≥ 1 LDL-C values during 
the follow-up period: only 37.4% of these patients achieved LDL-C target. 23.6% of 
patients underwent ≥ 1 CPK measurement: out of range values were identified in 
37.8% of them. Patients with steadily normal values of CPK showed a better medi-
cation-taking behavior compared to patients whose CPK values were out of normal 
range. Furthermore, a greater percentage of switching to other statin drug and/or 
dosage was observed in patients with out of range CPK levels compared to those with 
normal serum CPK levels ConClusions: Our findings indicate that physiological 
serum CPK levels were associated with greater adherence to statin therapy, sup-
porting a causal link between non-adherence behavior and muscle-related ADRs 
occurrence. Since statin benefits are associated with their chronic use, physicians 
should be aware about the relevance of monitoring their patients for this harmful 
link to prevent unsuitable therapeutic decisions, further decreasing adherence, and 
achieve long-term health outcomes
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objeCtives: This study evaluated the incidence and costs of lead damage within one 
year of pacemaker (PM), implantable cardiac defibrillator (ICD), and cardiac resynchro-
nization therapy defibrillator (CRT-D) device replacement. Methods: Using Truven 
US insurance claims (1/1/2009 – 12/31/2013), we identified patients who underwent 
a CIED generator replacement. We excluded patients with existing lead damage or 
active infection. Data were analyzed for one year prior to and following the replace-
ment procedure, with device replacement the index date for analysis. During follow-
up we considered lead damage to have occurred if there was any recorded visit with a 
procedure code for lead revision or repair and no concurrent code for infection. A Cox 
model, adjusted for baseline demographics and comorbidities, was used to evaluate 
variables associated with risk of lead damage. Results: The study cohort included 
45,250 patients (72±14 years; 64% male), including 22,557 (50%) PMs, 20,632 (46%) 
ICDs, and 2,061 (5%) CRT-Ds. Lead damage was observed in 406 (0.90%) patients. The 
incidence of lead damage was significantly influenced by CIED type (PM: 0.46%; ICD: 
1.27%; CRT: 1.94% p < .001). Similarly, total hospitalization cost associated with lead 
revision / repair was influenced by CIED type (PM: $19,959; ICD: $ 24,885; CRT: $46,229, 
p= 0.048). As compared to PMs, ICDs (HR = 2.14, 95% CI 1.68 – 2.74) and CRTs (HR = 2.97, 
95% CI 1.99 – 4.43) had a significantly higher risk of lead damage. ConClusions: 
This is the first nationally representative study to assess the incidence and associ-
ated costs of lead damage following CIED generator replacement in the US. Patients 
with an ICD or CRT have a significant 1-2% risk of lead damage, which is associated 
with substantial hospitalization-related costs. Strategies are needed at the time of 
generator replacement to minimize inadvertent lead damage.
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PreVention, treAtment And seCondAry PreVention of Venous 
thromboemboliC diseAse, And for PreVention of stroke in AtriAl 
fibrillAtion
Lopez-Lopez JA1, Sterne J1, Bodalia PN2, Bryden PA1, Davies P1, Okoli GN1, Thom H1, 
Caldwell DM1, Dias S1, Eaton D3, Higgins J1, Hollingworth W4, Salisbury C1, Savovic J1, 
Sofat R5, Stephens-Boal A6, Welton NJ1, Hingorani A5
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objeCtives: To determine the best oral anticoagulant(s) across four medical con-
ditions: stroke prevention in atrial fibrillation (AF), primary prevention of venous 
thromboembolic disease (VTE), acute treatment of VTE, and secondary prevention of 
VTE; using network meta-analysis to compare novel oral anticoagulants (NOACs) with 
warfarin and/or low molecular weight heparin (LMWH). Methods: We undertook 
four systematic reviews and network meta-analyses of randomised controlled trials. 
An extensive search and risk of bias assessment were followed by network meta-anal-
yses within each condition, and additionally we performed combined meta-analyses 
across the four reviews for key safety outcomes. Through consultation between clini-
cians and methodologists, we needed to make various decisions about groupings of 
interventions and doses, and of different endpoints, for analysis. Results: 85 trials 
were included across the reviews, including a mixture of phase III trials and phase 
II dose-ranging trials. For stroke prevention in AF, apixaban (5mg bd) was among the 
best interventions for a range of efficacy and safety outcomes with mean rank 2.35 
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objeCtives: Resistant hypertension (RH) is highly associated with cardiovascular 
risks. The difficulty in enrolling large numbers of study participants limits stud-
ies on treatment effects of RH. This study aims to compare the effectiveness of 
triple antihypertensive combination therapy for RH patients in Taiwan. Methods: 
Patients who had 3 antihypertensive agents of different classes concurrently pre-
scribed in outpatient clinics with their medication possession ratio ≧ 0.7 during 
2004-2006 were identified as the RH cases from the National Health Insurance 
Research database. The 1st outpatient visit with 3 antihypertensive agents of dif-
ferent classes being prescribed was defined as the index date. Patients were further 
classified into two treatment groups according to the combination of antihyper-
tensive therapy; the A+B+C group was defined as those who received concurrent 
therapy of ACEI/ARB in combination with beta-blocker and CCB, and the A+C+D 
group was those who received ACEI/ARB together with CCB and diuretics. The 
Cox proportional regression analysis was performed to investigate the risk of 
major adverse cardiovascular events (MACE) between the two treatment groups. 
Subgroup analysis was further performed by classifying patients into those with 
or without previous history of stroke, myocardial Infarction or end stage renal 
diseases. Results: There were 13,551 patients identified as the prevalence cases 
of RH during 2004-2006. Results showed the A+C+D group had a lower risk of 
MACE when compared to the A+B+C of group (adjusted HR= 1.11; 95%CI 1.01-1.22; 
p= 0.0272). Subgroup analysis showed there was no significant difference in the risk 
of MACE between the A+B+C and the A+C+D groups either in patients with prior 
disease history (adjusted HR = 1.10; 95%CI 0.96-1.25; p= 0.1881) or without prior 
disease history (adjusted HR = 1.12; 95%CI 0.99-1.28; p= 0.0767). ConClusions: 
The A+C+D combination therapy seemed to be more effective than the A+B+C 
therapy in preventing MACE among patients with RH.
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network metA-AnAlysis to Assess ComPArAtiVe effeCtiVeness of 
betA-bloCkers in PAtients with heArt fAilure And reduCed ejeCtion 
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objeCtives: Randomized trials have shown that blockade of beta adrener-
gic receptors leads to symptomatic improvement, reduced hospitalization and 
enhanced survival in many patients with heart failure (HF) and reduced ejec-
tion fraction. The objective of this study was to compare beta blockers for their 
efficacy in reducing mortality. Methods: A systematic literature search for 
randomized clinical trials for use of beta blockers in HF was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was col-
lected for the study type, methods, country and key findings. Extracted study 
data included study design, patient charatcertristcis and primary outcomes. A 
bayesian random effects network meta-analysis (NMA) model was developed in 
WinBUGS14. Results: We identified 830 references and found 21 randomized 
trials in 23,122 patients with 3,871 events. The treatments included in our study 
were Enalapril (E), Metoprolol (M), Atenolol (A), Bisoprolol (Bi), Bucindolol (Bu), 
Carvedilol (C), Metoprolol (M), Nebivolol (N) and placebo (P). All beta-blockers ver-
sus placebo were effective in reducing mortailty in HF and reduced ejection frac-
tion patients. Carvedilol ranked the highest with a Surface Under the Cumulative 
RAnking curve (SUCRA) score of 0.8672, Atenolol was second with score of 0.7035. 
SUCRA scores for other drugs were: Bisoprolol 0.6897, Metoprolol 0.6139, Nebivolol 
0.3704, Bucindolol 0.3519, Enalapriol 0.2635 and Placebo 0.1399. The odds ratios for 
Carvedilol and Atenolol versus placebo were 0.56 (0.43 – 0.71) and 0.54 (0.15 – 1.87), 
respectively. ConClusions: Network meta-analysis shows that Carvedilol ranks 
highest among beta-blockers for reduction in mortality in patients with heart 
failure and reduced ejection fraction.
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objeCtives: The National Institute for Health and Care Excellence in the United 
Kingdom (UK) recently issued guidance recommending the non-vitamin k antago-
nist oral anticoagulants (NOACs) rivaroxaban, dabigatran and apixaban for treatment 
and prevention of venous thromboembolism (VTE). An economic evaluation assess-
ing apixaban versus rivaroxaban and dabigatran found apixaban was associated 
with greater quality-adjusted life-years (QALYs) gained at a lower cost. Edoxaban, 
another NOAC, is poised to enter the (ex-United States [US]) market for the same 
indication. This analysis therefore evaluated the cost-effectiveness of apixaban 
compared to low molecular weight heparin (LMWH) followed by edoxaban from 
the perspective of the UK National Health Service. Methods: A Markov model 
was developed to evaluate the lifetime clinical and economic impact of six-month 
treatment following a VTE event with apixaban versus LMWH/edoxaban. The model 
included the following health states: recurrent VTE, major bleed, clinically relevant 
non-major bleed, chronic thromboembolic pulmonary hypertension, and death. 
Transition rates among health states were based upon AMPLIFY and AMPLIFY-EXT 
clinical trial data, network meta-analyses, and UK life tables. Cost and utilities 
were based on published estimates. Price parity with apixaban was assumed in 
the absence of any pricing information for edoxaban. Outcomes were life-years 
gained, QALYs gained, costs estimated in 2012 British pounds, and the incremental 
cost-effectiveness ratio (ICER). Results: Six-month treatment with apixaban was 
predicted to increase life expectancy and QALYs as compared to LMWH/edoxaban 
over a lifetime horizon. When these treatments were priced at parity, apixaban 
was associated with cost-savings due to avoided bleeds and higher cost of LMWH. 
Dominance was maintained even when edoxaban was priced at an 18% discount 
disease and obesity, as well as between sHTG and diabetes and acute pancreati-
tis. Patients with HTG received treatment with statins, fibrates, and omega-3 for-
mulations, including omega-3 ethyl esters and omega-3 fatty acids. Combination 
therapy was typically more effective at reducing TG levels than monotherapy. 
Economic data were reported only for sHTG patients in the United States (US) 
with annual direct costs from $8,000 -$9,000. Patients with TG levels > 17 mmol/L 
observed a marked increase in the total all-cause medical and pharmacy costs, 
which reached $12,642/year. Prescription omega-3 ethyl esters were cost-effective 
in the US based on a simulation model estimating $47,000/quality-adjusted life-year 
using a threshold of $50,000. Only two identified studies reported patient-centered 
outcomes. ConClusions: High HTG prevalence in various regions indicates dis-
ease burden is not effectively managed by current therapies and suggests a need for 
new treatments. Treating HTG and associated comorbidities results in a substantial 
economic burden. Further research is needed on the patient-centered burden of 
HTG and the economic impact of this disease, specifically in non-US locations and 
patients with TG levels ≥ 2.26 and < 5.6 mmol/L.
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objeCtives: Atrial fibrillation is the most common arrhythmia, affecting more 
than 4.5 million people in Europe. Owing to recent introduction of novel oral anti-
coagulant (NOACs) treatments in Germany, there is a need to generate real-world 
evidence on the profiles of patients with NVAF prescribed with such therapies. This 
study aimed to describe demographic and clinical characteristics of patients with 
NVAF newly prescribed NOACs in Germany. Methods: Retrospective cohort study 
of patients with NVAF who were newly prescribed with NOACs (index prescription) 
between December 2012 and October 2014, using German primary care data from 
IMS Disease Analyzer. We calculated summary statistics of demographic and clini-
cal characteristics in each NOAC therapy group. Results: Overall, 2,678 patients 
initiated apixaban, 2,696 dabigatran, and 9,562 rivaroxaban in the study period. At 
time of index NOAC initiation, mean age was 75.9 years (standard deviation 10.0; 
interquartile range 71-83) for apixaban, 74.5 (SD 10.3; IQR 69-82) for dabigatran, and 
74.7 (SD 10.4; IQR 69-82) for rivaroxaban. Across all NOAC therapies, around half 
were men and approximately 80% lived in West Germany. Patients on apixaban 
had higher rates of stroke risk factors such as hypertension (88.2% vs. 86.4% and 
85.4% for dabigatran and rivaroxaban, respectively); vascular diseases (61.3% vs. 
57.2% and 58.5%); and congestive heart failure (43.5% vs. 39.6% and 40.9%); and 
higher rate of bleeding history (30.0% vs. 27.1% and 27.8%). ConClusions: In 
routine clinical practice in Germany, patients newly treated with NOACs were 
elderly and frequently had comorbidities of cardiovascular importance such 
as hypertension and vascular diseases. Patients on apixaban had higher rates 
of stroke risk factors and bleeding history, which are likely to impact treat-
ment patterns and outcomes observed in this population. Future comparative 
effectiveness research across NOACs should account for channeling in patient 
profiles.
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objeCtives: To review trends in pulmonary embolism-related discharges and 
understand sociodemographic and seasonal factors correlated with a PE diagnosis 
among hospitalized Spanish patients. Methods: Using hospital discharge data 
from the Encuesta de Morbilidad Hospitalaria we analyzed trends in PE-related 
hospital discharges in Spanish hospitals from 2008 to 2011. PE was defined based on 
principal diagnosis ICD-9 codes 41511 (Iatrogenic pulmonary embolism and infarc-
tion), 41512 (septic pulmonary embolism), 41513 (saddle embolus of pulmonary 
artery), and 41519 (other pulmonary embolism and infarction). The principal diag-
nosis was established to be the primary reason the patient was hospitalized. Results 
were stratified by age, sex, province and season of the year. We used log-binomial 
and logistic regression models to evaluate the relationship between these char-
acteristics and a diagnosis of PE. Results: Of the 18,317,000 hospital admissions 
over the 4-year period, 56,600 (0.31%) were primarily PE-related. The proportion of 
PE diagnosis of all hospitalizations remained steady, ranging from 0.28%- 0.34%. PE 
risk was similar among males and females; risk ratio (RR) 1.03 95% CI (1.04-1.07). 
PE-related hospitalizations increased with age however, rates were higher in men 
65 years and younger than their female counterparts and higher in women 70 and 
older than their male counterparts. The greatest change (30% increase) in diagnosis 
from 2008-2011 was among 40-59 year olds and people over 80. We found a seasonal 
variation in PE diagnosis, with lowest rates of diagnosis in April to July in both 
males and females, over the 4-year period. PE hospitalization rates were two times 
higher in the northern than southern regions RR 1.82(1.76-1.88). ConClusions: 
Age, gender, geographic location and month of the year were correlated with diag-
nosis of PE among hospitalized Spanish patients. A future area of research is to 
clarify these relationships and determine possible interventions to reduce PE in 
these populations.
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